Detalhe da pesquisa
1.
The Inherent Unfairness of COVID-19 Drug Access Pathways.
Am J Bioeth
; 20(9): 18-20, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33505223
2.
Real-World Data Collection from Expanded Access Case Studies for the Treatment of Nontuberculous Mycobacterial Infection with Clofazimine.
medRxiv
; 2023 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37961189
3.
National landscape assessment of academic medical center support for expanded access to investigational products.
J Clin Transl Sci
; 7(1): e4, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36755539
4.
Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case Series.
Open Forum Infect Dis
; 10(4): ofad189, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37089775
5.
Adapting an Expanded Access program to enable investigational treatments for COVID-19.
J Clin Transl Sci
; 6(1): e77, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35836783
6.
Role of CTSA institutes and academic medical centers in facilitating preapproval access to investigational agents and devices during the COVID-19 pandemic.
J Clin Transl Sci
; 5(1): e94, 2021 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192051
7.
The Critical Role of Medical Institutions in Expanding Access to Investigational Interventions.
Hastings Cent Rep
; 49(2): 36-39, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30998277
8.
Right now, in the right way: U. S. Food and Drug Administration's expanded access program and patient rights.
J Clin Transl Sci
; 2(3): 115-117, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30370061